Biogen Inc
NASDAQ:BIIB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
146.47
267.71
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Biogen Inc
Wall Street
Price Targets
BIIB Price Targets Summary
Biogen Inc
According to Wall Street analysts, the average 1-year price target for
BIIB
is 254.44 USD
with a low forecast of 185.84 USD and a high forecast of 359.1 USD.
BIIB Last Price Targets
Biogen Inc
The latest public price target was made on Nov 15, 2024 by
Brian Skorney
from
Robert W. Baird
,
who expects
BIIB
stock to
rise by 105%
over the next 12 months.
You can read more about this price target by viewing
the article on StreetInsider.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Brian Skorney
Robert W. Baird
|
300
USD
Upside 105% |
1 month ago
Nov 15, 2024
|
Biogen (BIIB) PT Raised to $300 at Baird
StreetInsider
|
Jay Olson
Oppenheimer
|
255
USD
Upside 74% |
1 month ago
Oct 31, 2024
|
Biogen (BIIB) PT Lowered to $255 at Oppenheimer
StreetInsider
|
Terence Flynn
Morgan Stanley
|
204
USD
Upside 39% |
1 month ago
Oct 31, 2024
|
Biogen downgraded to Equal Weight from Overweight at Morgan Stanley
TheFly
|
Salveen Richter
Goldman Sachs
|
290
USD
Upside 98% |
1 month ago
Oct 30, 2024
|
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB)
StreetInsider
|
Christopher Raymond
Raymond James
|
315
USD
Upside 115% |
1 month ago
Oct 30, 2024
|
Biogen (BIIB) PT Raised to $315 at Piper Sandler
StreetInsider
|
Evan Seigerman
BMO Capital
|
230
USD
Upside 57% |
2 months ago
Oct 17, 2024
|
Biogen price target lowered to $230 from $260 at BMO Capital
TheFly
|
Ashwani Verma
UBS
|
202
USD
Upside 38% |
2 months ago
Oct 3, 2024
|
Biogen price target lowered to $202 from $234 at UBS
TheFly
|
Laura Chico
Wedbush
|
205
USD
Upside 40% |
3 months ago
Sep 23, 2024
|
Biogen price target lowered to $205 from $210 at Wedbush
TheFly
|
|
Brian Skorney
Robert W. Baird
|
294
USD
Upside 101% |
4 months ago
Jul 29, 2024
|
Biogen (BIIB) PT Lowered to $294 at Baird
StreetInsider
|
|
Salveen Richter
Goldman Sachs
|
342
USD
Upside 133% |
4 months ago
Jul 26, 2024
|
Goldman Sachs Reiterates Buy Rating on Biogen (BIIB), 'We next await the August 1 earnings call'
StreetInsider
|
Brian Abrahams
RBC Capital
|
282
USD
Upside 93% |
4 months ago
Jul 26, 2024
|
Biogen (BIIB) PT Lowered to $282 at RBC Capital
StreetInsider
|
Christopher Raymond
Piper Sandler
|
307
USD
Upside 110% |
4 months ago
Jul 26, 2024
|
Biogen (BIIB) PT Lowered to $307 at Piper Sandler
StreetInsider
|
|
Christopher Raymond
Piper Sandler
|
313
USD
Upside 114% |
5 months ago
Jul 12, 2024
|
Biogen price target lowered to $313 from $335 at Piper Sandler
TheFly
|
|
Terence Flynn
Morgan Stanley
|
311
USD
Upside 112% |
5 months ago
Jul 11, 2024
|
Biogen price target lowered to $311 from $331 at Morgan Stanley
TheFly
|
George Farmer
Scotiabank
|
275
USD
Upside 88% |
6 months ago
Jun 12, 2024
|
Scotiabank Reiterates Sector Outperform Rating on Biogen (BIIB)
StreetInsider
|
|
Evan David Seigerman
BMO Capital
|
260
USD
Upside 78% |
7 months ago
May 23, 2024
|
BMO Capital Reiterates Outperform Rating on Biogen (BIIB)
StreetInsider
|
|
Matthew Harrison
Morgan Stanley
|
331
USD
Upside 126% |
7 months ago
May 22, 2024
|
Morgan Stanley on Biogen (BIIB) Acquisition of Hi-Bio
StreetInsider
|
Paul Matteis
Stifel Nicolaus
|
275
USD
Upside 88% |
7 months ago
May 22, 2024
|
Stifel Reiterates Buy Rating on Biogen (BIIB) Following Acquisition of HI-Bio
StreetInsider
|
|
Christopher Raymond
Raymond James
|
335
USD
Upside 129% |
7 months ago
May 22, 2024
|
Piper Sandler Reiterates Overweight Rating on Biogen (BIIB) Following Acquisition of HI-Bio
StreetInsider
|
|
Laura Chico
Wedbush
|
215
USD
Upside 47% |
7 months ago
Apr 25, 2024
|
Biogen price target raised to $215 from $213 at Wedbush
TheFly
|
|
Andrew Fein
H.C. Wainwright
|
300
USD
Upside 105% |
7 months ago
Apr 25, 2024
|
Biogen (BIIB) PT Lowered to $300 at H.C. Wainwright
StreetInsider
|
|
Brian Abrahams
RBC Capital
|
317
USD
Upside 116% |
7 months ago
Apr 25, 2024
|
Biogen (BIIB) PT Lowered to $317 at RBC Capital
StreetInsider
|
|
Jay Olson
Oppenheimer
|
270
USD
Upside 84% |
8 months ago
Apr 19, 2024
|
Biogen (BIIB) PT Lowered to $270 at Oppenheimer
StreetInsider
|
Carter Gould
Barclays
|
215
USD
Upside 47% |
8 months ago
Apr 3, 2024
|
Biogen price target lowered to $215 from $230 at Barclays
TheFly
|
|
Laura Chico
Wedbush
|
269
USD
Upside 84% |
1 year ago
Aug 7, 2023
|
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
Benzinga
|
Yatin Suneja
Guggenheim
|
350
USD
Upside 139% |
1 year ago
May 1, 2023
|
Biotech Is Back With Guggenheim Upgrade: What You Need To Know
Benzinga
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is BIIB's stock price target?
Price Target
254.44
USD
According to Wall Street analysts, the average 1-year price target for
BIIB
is 254.44 USD
with a low forecast of 185.84 USD and a high forecast of 359.1 USD.
What is Biogen Inc's Revenue forecast?
Projected CAGR
1%
For the last 8 years the
compound annual growth rate for
Biogen Inc's revenue is
-1%.
The projected
CAGR
for the next 4 years is
1%.
What is Biogen Inc's Operating Income forecast?
Projected CAGR
12%
For the last 8 years the
compound annual growth rate for
Biogen Inc's operating income is
-10%.
The projected
CAGR
for the next 4 years is
12%.
What is Biogen Inc's Net Income forecast?
Projected CAGR
25%
For the last 8 years the
compound annual growth rate for
Biogen Inc's net income is
-13%.
The projected
CAGR
for the next 4 years is
25%.
You don't have any saved screeners yet
